This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ribas, A. Articles by Cochran, A. J. Search for Related Content PubMed PubMed Citation Articles by Ribas, A. Articles by Cochran, A. J.

Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

Authors' Affiliations: ¹ Division of Hematology/Oncology, Department of Medicine, ² Division of Surgical Oncology, Department of Surgery, ³ Jonsson Comprehensive Cancer Center, and ⁴ Department of Microbiology, Immunology and Molecular Genetics, and ⁵ Department of Pathology and Laboratory Medicine, University of California-Los Angeles, Los Angeles, California; and ⁶ Pfizer Global Research and Development, New London, Connecticut

Requests for reprints: Antoni Ribas, Division of Hematology/Oncology, Department of Medicine, University of California-Los Angeles Medical Center, 11-934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782. Phone: 310-206-3928; Fax: 310-206-0914; E-mail: aribas{at}mednet.ucla.edu.

Purpose: CTL-associated antigen 4 (CTLA4)-blocking monoclonal antibodies induce long-term regression of metastatic melanoma in some patients, but the exact mechanism is unknown. In this study, biopsies of selected accessible tumor lesions from patients treated with tremelimumab were examined to further elucidate the mechanism of its antitumor activity.

Experimental Design: Fifteen tumor biopsies from 7 patients who had been treated with tremelimumab (CP-675,206) were collected. Samples were analyzed for melanoma markers, immune cell subset markers, the presence of the T regulatory-specific transcription factor FoxP3 and the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO).

Results: Clinically responding lesions had diffuse intratumoral infiltrates of CD8⁺ T cells that were markedly increased in cases where comparison with a baseline biopsy was available. Nonregressing lesions had sparse, patchy CD8⁺ intratumoral infiltrates. Patients with regressing lesions had an increased frequency of CD8⁺ cells with or without a concomitant increase in CD4⁺ cells. Two of 3 responding patients with paired samples showed a slight increase in the number of FoxP3⁺ cells in the postdosing biopsies. In patients with regressing lesions who had paired samples, the intensity of IDO staining in macrophages and/or melanoma cells showed no clear pattern of change postdosing.

Conclusions: Administration of tremelimumab was associated with massive intratumoral infiltrates of CD8⁺ CTLs in patients with regressing tumors but had varying effects on intratumoral infiltrates of CD4⁺ and FoxP3⁺ cells or intratumoral expression of IDO.